Showing 4351-4360 of 5646 results for "".
- Glaukos Announces Licensing Agreement with Attillaps Holdingshttps://modernod.com/news/glaukos-announces-licensing-agreement-with-attillaps-holdings-inc/2480289/Glaukos announced that it has entered into a licensing agreement with Attillaps Holdings under which Glaukos will gain a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compound
- First Ophthalmology Biosimilar Approved in the United Stateshttps://modernod.com/news/fda-approves-samsung-bioepis-and-biogens-byooviz-lucentis-biosimilar-ranibizumab-nuna/2480286/Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (R
- Luneau Technology and Optovue Announce Mergerhttps://modernod.com/news/luneau-technology-and-optovue-announce-merger/2480284/France-based Luneau Technology Group, a provider of wavefront-based diagnostic and finishing solutions, announced it is merging with Optovue. Terms of the deal were not disclosed. Founded by Jay Wei in 2003, Optovue develops high-speed OCT and OCT-A technology
- Sight Sciences Files Lawsuit Against Ivantis for Patent Infringementhttps://modernod.com/news/sight-sciences-files-lawsuit-against-ivantis-for-patent-infringement/2480283/Sight Sciences announced that it has filed a lawsuit in the United States District Court in Delaware against Ivantis for infringement of U.S. Patents that describe and claim devices and methods for reducing intraocular pressure in the eye. The patents are Numbers 8,287,48
- Aurion Biotech Announces Strategic Investments in Manufacturinghttps://modernod.com/news/aurion-biotech-announces-strategic-investments-in-manufacturing/2480275/Aurion Biotech announced it has appointed Tim Largen as vice president of manufacturing. Mr. Largen is based in Seattle and will lead strategy and development of Aurion Biotech’s global cell manufacturing capabilities. His role will include managing Aurion Biotech’s internal team and
- AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-eye-care-collaboration/2479577/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patient
- World Council of Optometry Launches Myopia Management Online Resourcehttps://modernod.com/news/world-council-of-optometry-launches-myopia-management-online-resource/2479506/Building upon their efforts to establish a standard of care for myopia management, the World Council of Optometry (WCO) and CooperVision have jointly developed an easy-to-use online resource that provides multilingual assets and approaches that will enable busy eye care professionals—regardless o
- NIH-Funded Robotic Cane With 3D Camera Can Accurately Guide User to Chosen Locationhttps://modernod.com/news/nih-funded-robotic-cane-with-3d-camera-can-accurately-guide-user-to-chosen-location/2479504/Equipped with a color 3D camera, an inertial measurement sensor, and its own on-board computer, a newly improved robotic cane could offer blind and visually impaired users a new way to navigate indoors. When paired with a building’s architectural drawing, the device can accurately guide a user to
- Apellis Reports Mixed Phase 3 Results for Geographic Atrophy Drug; Will Pursue FDA Approvalhttps://modernod.com/news/apellis-announces-topline-results-from-phase-3-derby-and-oaks-studies-in-geographic-atrophy/2479503/Apellis Pharmaceuticals reported topline results from the phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). B
- Oertli Launches Updated Faros Surgical Platformhttps://modernod.com/news/oertli-launches-updated-faros-surgical-platform/2479501/Oertli has updated its Faros surgical platform with new LED technology. The compact device for anterior and posterior segment surgery provides 45% more light output, and ensures optimal illumination and visualization, according to a company news release. Oertli’s Faros device performs cat